Artificial Organs and Bionics Market is set for steady growth to US$ 77.08 billion by 2031, led by North America 46.5% of global market share.

The Global Artificial Organs and Bionics Market reached US$ 37.85 billion in 2023 and is expected to reach US$ 77.08 billion by 2031, growing at a CAGR of 9.3% during the forecast period 2024-2031.

Market growth is driven by the rising prevalence of organ failure and chronic diseases, increasing adoption of advanced artificial organs and bionic solutions, and growing awareness of organ transplantation alternatives. Additionally, advancements in biocompatible materials and smart bionic devices, expanding use in post-transplant and rehabilitative care, and improving healthcare infrastructure and reimbursement scenarios are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/artificial-organs-and-bionics-market?pratik

United States: Key Industry Developments
✅ December 2025: Abbott Laboratories received FDA approval for its next-generation artificial heart pump with bio-integrated sensors, enhancing blood flow regulation by 25% and reducing thrombosis risks for end-stage heart failure patients awaiting transplants.​

✅ October 2025: Medtronic launched an advanced bionic limb system featuring neural interface controls and AI-adaptive prosthetics, improving gait stability and user mobility for amputees in rehabilitation programs nationwide.

✅ August 2025: Boston Scientific expanded its artificial organ portfolio with a bioartificial kidney prototype trial, incorporating glomerular filtration tech to support dialysis patients and address chronic kidney disease prevalence.

Asia Pacific / Japan: Key Industry Developments
✅ November 2025: Terumo Corporation introduced its implantable bio-lung device in Japan, offering gas exchange efficiency surpassing traditional ECMO by 40% for acute respiratory failure cases in aging populations.

✅ September 2025: Japanese regulators approved subsidies for bionic exoskeleton adoption in eldercare, with Cyberdyne's HAL system upgrades enabling precise muscle support and fall prevention amid rising dementia-related mobility issues.

✅ July 2025: Nipro collaborated on a fully implantable artificial pancreas launch, integrating glucose-responsive insulin delivery for Type 1 diabetes management, aligning with Japan's precision medicine initiatives and device innovation funding.

Recent M&A Activity:-
✅Bioness Medical, Inc. acquires Harmonic Bionics, Inc. (U.S.) - Bioness Medical, a neuro‐rehabilitation specialist, acquired the assets and business of Harmonic Bionics, an Austin‐based robotics company focused on upper‐extremity exoskeleton systems for stroke and traumatic brain injury patients. This deal expands Bioness' bionics portfolio beyond gait and balance solutions into bilateral upper‐limb robotic therapy, integrating Harmonic Bionics' exoskeleton that synchronizes with scapulohumeral rhythm to deliver more natural arm and shoulder rehabilitation within advanced neuro‐rehab programs.
​
✅Applied Digital's cloud unit merger with Ekso Bionics to form ChronoScale (U.S.) - Applied Digital announced the spin‐off and merger of its cloud computing division with exoskeleton pioneer Ekso Bionics, creating ChronoScale Corporation, a specialized AI‐GPU infrastructure company with approximately 97% post‐deal ownership held by Applied Digital. While primarily an AI infrastructure transaction, Ekso Bionics' exoskeleton expertise brings a strategic pathway to embed high‐performance AI and edge computing into next‐generation bionic systems, indirectly reinforcing capabilities around AI‐driven rehabilitation and occupational exoskeleton platforms within the broader bionics ecosystem.

Market Segmentation Analysis:
By Type
Artificial organs dominate the Artificial Organs and Bionics Market with approximately 60-65% market share in 2025, driven by demand for kidney and heart replacements amid organ shortages.
​Bionics hold the remaining 35-40%, fueled by advancements in prosthetic limbs and neural interfaces.
​
By Material
Mechanical materials lead with 68% share in 2024, preferred for their durability in load-bearing applications like artificial hearts.
​Electronic materials capture around 55% in bionic implants, growing at 9.92% CAGR due to integration with IoT for real-time monitoring.
​Biohybrid and other biomaterials follow, gaining traction for biocompatibility in tissue-engineered organs.
​
By Fixation Type
Implantable fixation types command over 70% share, favored for permanent solutions in high-risk patients requiring seamless integration.​
External fixation holds the rest, adopted for transitional care with non-invasive adjustability.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=artificial-organs-and-bionics-market?pratik

Growth Drivers:-
Rising prevalence of cardiovascular and chronic diseases.
Increasing geriatric population requiring organ replacement.
Advancements in bionic and implantable medical devices.
Growing adoption of minimally invasive and non-invasive procedures.
Increasing healthcare expenditure and access to advanced treatments.
Technological innovations in tissue engineering and regenerative medicine.
Rising awareness and acceptance of artificial organ solutions.

Regional Insights:
North America commands the largest share of the Artificial Organs and Bionics Market, estimated at around 46.5% in recent assessments, driven by advanced healthcare infrastructure, high prevalence of organ failures, substantial R&D investments, and favorable reimbursement policies in the US and Canada.
​
Europe follows as the second-largest region, benefiting from established medical device regulations, rising adoption in countries like Germany, the UK, and France, and growing awareness of prosthetic solutions, though exact shares vary by report amid steady market expansion.
​
Asia Pacific ranks third in market share, yet exhibits the fastest growth potential with high CAGRs in nations such as China, India, and Japan, fueled by increasing healthcare investments, government subsidies for medical devices, and expanding geriatric populations.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/artificial-organs-and-bionics-market?pratik

Key Players:
The major global players in the artificial organs and bionics market include Abiomed Inc. (Johnson & Johnson Services, Inc.), SynCardia Systems, LLC, Medtronic, Boston Scientific Corporation, Zimmer Biomet., Edwards Lifesciences Corporation., Jarvik Heart, Inc., Cochlear Ltd., Berlin Heart and Ekso Bionics among others.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.